Fig. 3: Fluorescent in situ hybridization (FISH) outlines spectrum of HER2 heterogeneity. | Nature Communications

Fig. 3: Fluorescent in situ hybridization (FISH) outlines spectrum of HER2 heterogeneity.

From: Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma

Fig. 3

A Fraction of cells displaying HER2 amplifications as determined by single cell HER2 FISH shows significant heterogeneity. A minimum of 50 tumor nuclei were measured to determine HER2 amplified fraction (y-axis) (N = 14) B Representative images from HER2 FISH showing absent (left), intermediate (middle) and high levels (right) of HER2 heterogeneity. Red probe binds HER2 locus, and green probe binds centromeric region of chromosome 17 (CEP17). Ratio of HER2/CEP17 is used to identify HER2 amplification and polysomy chromosome 17. Middle panel: Normal tissue provides contrast with no evidence of HER2 amplification. Blue dashed circles: HER2 negative cells, Red dashed circle: HER2 positive cells. C. HER2 2 + IHC (n = 3) tumors show significantly higher HER2 heterogeneity or lower HER2 amplified fraction compared to HER2 3 + IHC (n = 10). Dots represent individual patients, box extends from 25th to 75th percentile, horizontal line within box represents median, and whiskers extend a maximum of 1.5 x interquartile range (IQR). A, C. Groups compared using two-tailed Wilcoxon rank-sum test C.

Back to article page